Table 6. Individual studies evaluating HR between IGF-1 and cancer.

Study	Control	Cancer cases	HR	HR 95% CI - Lower	HR 95% CI - Upper	Weight in meta-analysis
1. Endogenous Hormones, T. E., & Breast Cancer Collaborative Group, 2010 190	9,428	4,790	1.28	1.14	1.44	17.28
2. Gunter et al., 2009 189	841	810	1.46	1.00	2.13	8.09
3. Annekatrin et al., 2002 166	263	132	4.97	1.22	20.2	8.72
4. Renehan et al., 2000 164	293	52	3.05	2.04	4.57	0.21
5. Renehan et al., 2004 167	7137	3609	1.49	1.14	1.95	2.51
6. Rinaldi et al., 2010 171	1121	1121	1.43	1.13	1.93	10.72
7. Roddam et al., 2008 169	5200	3700	1.38	1.16	1.60	12.21
8. Allen et al., 2007 168	630	630	1.39	1.02	1.89	14.77
9. Mikami et al., 2009 183	302	101	1.01	0.49	2.10	10.2
10. Spitz et al., 2002 188	297	297	2.21	0.35	12.84	6.98
11. Major et al., 2010 181	559	74	1.61	1.28	2.02	5.13
12. Hankinson et al., 1998 186	620	397	2.33	1.06	5.16	3.23
13. Yu et al., 1999 187	218	204	2.06	1.19	3.56	17.28
Total	26,909	15,917
Meta analyses
14. Shi et al., 2004 191	6030-1017	30-397	1.05	0.94	1.17

Note: HR was calculated for cancer vs. non cancer.